Janet H Young

Address:

825 Johns Rd APT 112, Boerne, TX 78006

VIN:

4T1BK36B28U294143

Make:

TOYOTA

Model:

AVALON

Year:

2008

US Patent:

7060103, Jun 13, 2006

Filed:

Feb 28, 2003

Appl. No.:

10/376788

Inventors:

Kimberlie D. Condon - Brant Rock MA, US
Paul L. Termin - St. Paul MN, US
Janet Hardin Young - Cary NC, US

Assignee:

Organogenesis Inc. - Canton MA

International Classification:

A61F 2/02

US Classification:

623 2372, 623 144, 623915, 623917, 606151

Abstract:

A prosthesis, which, when implanted into a mammalian patient, serves as a functioning replacement for a body part, or tissue structure, and will undergo controlled biodegradation occurring concomitantly with bioremodeling by the patients living cells. The prosthesis is treated so that it is rendered non-antigenic so as not to elicit a significant humoral immune response. The prosthesis, in its various embodiments, thus has dual properties. First, it functions as a substitute body part, and second, it functions as bioremodeling template for the ingrowth of host cells.

US Patent:

7909886, Mar 22, 2011

Filed:

Mar 24, 2006

Appl. No.:

11/277406

Inventors:

Kimberlie D. Condon - Brant Rock MA, US
Paul L. Termin - St. Paul MN, US
Janet Hardin Young - Cary NC, US

Assignee:

Organogenesis, Inc. - Canton MA

International Classification:

A61F 2/06
A61B 17/08

US Classification:

623917, 623 147, 606154

Abstract:

This invention is directed to prosthesis, which, when implanted into a mammalian patient, serves as a functioning replacement for a body part, or tissue structure, and will undergo controlled biodegradation occurring concomitantly with bioremodeling by the patient's living cells. The prosthesis is treated so that it is rendered non-antigenic so as not to elicit a significant humoral immune response. The prosthesis of this invention, in its various embodiments, thus has dual properties. First, it functions as a substitute body part, and second, it functions as bioremodeling template for the ingrowth of host cells.

US Patent:

20130273083, Oct 17, 2013

Filed:

Feb 22, 2013

Appl. No.:

13/774644

Inventors:

INGENIUM BIOTHERAPY CORPORATION - , US
Joseph C. Laning - Southborough MA, US
Janet H. Young - Boerne TX, US

Assignee:

INGENIUM BIOTHERAPY CORPORATION - Benson VT

International Classification:

G01N 33/574
C07K 14/705
C07K 14/74

US Classification:

4241841, 530350, 530395, 435 34, 435 723

Abstract:

Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, T cells can be genetically altered to target these antigens and then used for personalized T cell therapy. A method to identify and select peptide antigens that effectively associate with and are presented by host HLA surface molecules originating from tumor cells responsible for the persistence and propagation of a cancer has been developed. The system of using these data to produce T cells engineered to express T cell receptors recognizing the peptide antigens is used in the production of a personalized adoptive T cell therapy for cancer that eliminates the cells capable of tumor propagation and cancer progression. The system is especially useful in the production of cancer treatments to achieve complete durable remission of cancers of epithelial origin.

US Patent:

20210278407, Sep 9, 2021

Filed:

May 24, 2021

Appl. No.:

17/328465

Inventors:

- Newton MA, US
Joseph Laning - Southborough MA, US
Janet Young - Boerne TX, US

International Classification:

G01N 33/569
A61K 39/00
G01N 33/50
G01N 33/574
A61K 35/17
C07K 14/47

Abstract:

A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprograming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.

US Patent:

20190353655, Nov 21, 2019

Filed:

Jun 10, 2019

Appl. No.:

16/436344

Inventors:

Joseph Laning - Southborough MA, US
Janet Young - Boerne TX, US

International Classification:

G01N 33/569
A61K 39/00
G01N 33/574
G01N 33/50
A61K 35/17
C07K 14/47

Abstract:

A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprograming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.

US Patent:

20180252719, Sep 6, 2018

Filed:

May 8, 2018

Appl. No.:

15/974276

Inventors:

- Southborough MA, US
Joseph Charles Laning - Southborough MA, US
Janet Hardin Young - Boerne TX, US

International Classification:

G01N 33/574
A61K 35/17
A61K 38/17
C07K 14/705
C07K 14/74
C12N 5/0783
C12N 5/09
C12N 5/095
G01N 33/50

Abstract:

Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, T cells can be genetically altered to target these antigens and then used for personalized T cell therapy. A method to identify and select peptide antigens that effectively associate with and are presented by host HLA surface molecules originating from tumor cells responsible for the persistence and propagation of a cancer has been developed. The system of using these data to produce T cells engineered to express T cell receptors recognizing the peptide antigens is used in the production of a personalized adoptive T cell therapy for cancer that eliminates the cells capable of tumor propagation and cancer progression. The system is especially useful in the production of cancer treatments to achieve complete durable remission of cancers of epithelial origin.

US Patent:

20160161486, Jun 9, 2016

Filed:

Dec 3, 2015

Appl. No.:

14/958780

Inventors:

- Southborough MA, US
Joseph Laning - Southborough MA, US
Janet Young - Boerne TX, US

International Classification:

G01N 33/569
C07K 14/47
A61K 35/17

Abstract:

A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprogramming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.

US Patent:

20160161488, Jun 9, 2016

Filed:

Feb 12, 2016

Appl. No.:

15/042748

Inventors:

- Southborough MA, US
Joseph C. Laning - Southborough MA, US
Janet H. Young - Boerne TX, US

International Classification:

G01N 33/574
C12N 5/09

Abstract:

Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, T cells can be genetically altered to target these antigens and then used for personalized T cell therapy. A method to identify and select peptide antigens that effectively associate with and are presented by host HLA surface molecules originating from tumor cells responsible for the persistence and propagation of a cancer has been developed. The system of using these data to produce T cells engineered to express T cell receptors recognizing the peptide antigens is used in the production of a personalized adoptive T cell therapy for cancer that eliminates the cells capable of tumor propagation and cancer progression. The system is especially useful in the production of cancer treatments to achieve complete durable remission of cancers of epithelial origin.